Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 11/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449234 | 1.00 | CCR2 (0.49) | CCR2HTR2CEPHX1KDM1ACCR3 | |
| SCHEMBL4850026 | 0.88 | CCR2 (0.62) | CCR2CCR3RXFP1 | |
| SCHEMBL4850015 | 0.88 | CCR2 (0.62) | CCR2CCR3RXFP1 | |
| SCHEMBL4839187 | 0.85 | CCR2 (0.46) | CCR2HTR2CEPHX1KDM1ARXFP1 | |
| SCHEMBL4847640 | 0.82 | CCR2 (0.61) | CCR2HTR2CEPHX1CCR3 | |
| SCHEMBL4849796 | 0.82 | CCR2 (0.61) | CCR2HTR2CEPHX1CCR3 | |
| Acetic Acid SCHEMBL5702362 | 0.81 | CCR2 (0.57) | CCR2HTR2CEPHX1KDM1ACCR3 | |
| Acetic Acid SCHEMBL5702355 | 0.81 | CCR2 (0.57) | CCR2HTR2CEPHX1KDM1ACCR3 | |
| SCHEMBL4839183 | 0.81 | CCR2 (0.41) | CCR2HTR2CEPHX1RXFP1IGF2BP2 | |
| SCHEMBL2991053 | 0.80 | IGF2BP2 (0.46) | CCR2RXFP1IGF2BP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | TEIJIN PHARMA LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1676837-A1 | PROCESS FOR PRODUCING AMINOPYRROLIDINE DERIVATIVE AND INTERMEDIATE COMPOUND | Teijin Pharma Limited (JP) | 2006-07-05 | — | — | EP | disclosed |
| EP-1179341-B1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1553085-A1 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1535909-A2 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6451842-B1 | Cyclic amine derivatives and their use as drugs | DUPONT PHARMACEUTICALS COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6410566-B1 | ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6362177-B1 | INHIBITION OF CHEMOKINE BINDING | TEIJIN LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1179341-A1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073064-A1 | Method for producing aminopyrrolidine derivatives and intermediate compounds | ACKR3, CCR2, CCR5 | CCR2 2/4885HTR2C 454/4885EPHX1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.